The IPKat

MAY 12, 2024

The UPCKat trying to keep confidential information confidential in the UPC As part of our UPCKat reporting on the latest UPC developments, the IPKat brings readers a roundup of how the UPC is treating confidentiality and third party access to court documents.

Confidentiality 61

Confidentiality Art Patent Patent Application 61

The IPKat

JUNE 22, 2023

Mellor J, the Judge, explained that in very general terms he adopted the same approach as that of Birss J in Unwired Planet v Huawei [2017] EWHC 711 (Pat) ([42]). The Judge decided to adopt the same approach as in Unwired Planet v Huawei [2017] EWHC 711 (Pat) and in the US judgment TCL v Ericsson (C.D. 21, 2017) (Selna, J.)

Patent Infringement 86

Patent Infringement Licensing Patent Litigation 86

The IPKat

DECEMBER 22, 2022

An Arrow declaration is a declaration that a product, process or use was lacking in novelty or obvious as at the priority date of a patent application. The declaration means that the applicant will have a Gillette defence to patent infringement claims about that product, process, or use. The Judge dismissed this submission.

Marketing 81

Marketing Marketing Patent Infringement Patent 81

The IPKat

SEPTEMBER 12, 2021

A primary motivation for Abbott's expedition application was to obtain a UK court decision on the validity of four European patents in order to influence a German court considering infringement of the German EP equivalents and to prevent the problems of the "injunction gap". Libre 2 was launched in October 2020.

Litigation 98

Litigation Patent Marketing Marketing 98

Patently-O

FEBRUARY 22, 2023

Patent assertion finance today is a multibillion-dollar business. [2] 2] Virtually nonexistent in the patent space in the U.S. It generally amounts to more than 50% of the total settlement recovery, acknowledging, at least by basic math, that they are the primary beneficiary of the litigation.).

Litigation 124

Litigation Reporting Settlement Government 124

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Yet, given fewer FDA approvals in 2020 and 2021, this year saw the lowest number of commercial launches since 2017. Then, on October 15, 2021, FDA approved a second interchangeable biosimilar, Boehringer Ingelheim’s (BI) Cyltezo ® (adalimumab-adbm) (Cyltezo ® was previously approved as a biosimilar in 2017). Commercial Launch Date.

Litigation 52

Litigation Settlement Patent Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 5, 2022

For example, patents protect inventions, whereas copyrights protect written or recorded expressive content; trademarks protect words, symbols, logos, designs, and slogans that identify or distinguish products or services; and trade secrets protect confidential business information. Standard Setting Organizations and Patent Pools.

Intellectual Property 52

Intellectual Property Technology Journalism IP 52